Anthony Petrone

Is there any major difference in the margin profile of office surgical and fertility

what was the percent of private label exiting last fiscal year? And with the addition of these new private label contracts, where can that increase to?

maybe can you size that in terms of the number of target practices you're going after? Like how many sites are you looking to penetrate?

On CVI, maybe a little bit on the private label business. How that trended in the fiscal year?

Could you talk about your expectations for '26?

do you think there is any risk just on a destock or a tighter inventory situation in contact lenses

You mentioned a little bit on an inventory contraction. So you had strong back-to-school fits. But then in October, you had inventory contraction

SiHy daily torics in particular, silicone hydrogel daily torics are margin accretive to the business

How do you level set expectations on what we should be looking for for a statistically meaningful A1c reduction out of the RCT

how long do you think it will take to fully roll over the 10-day to 15-day? And what does that do to gross margin

Do you have any data on that? Are you noticing more utilization intensity with prediabetics

where do you see severe asymptomatic for mitral from minimally invasive in terms of penetration? And what do you think can happen when we get more data potentially from competition here early next ...

a little bit on the U.S. TAVR backlog. It typically sits at around somewhere in the 3- to 6-month range and with asymptomatic not being in there in this quarter

what do you actually have baked in there from a tariff impact for 2026?

when you think about AI-enabled platforms, you have Intelerad in there

Maybe one will be on just, you know, how much price is actually in there just considering you have a fair amount of new product introductions

I saw you guys signed a distribution agreement with CDL on your pharma diagnostics side for [ Flyrcado ]. Is -- my understanding was CDL represents maybe

what is -- I'm assuming semiconductor impacts are reflected in your net $0.85 impact

when you think about potential upside to that, is that more contingent on just rate of adoption at the nuclear medicine level

if we have normalization in China, is it fair to say that this could be an upside case to the mid-20s on the margin side over time

walk us through a little bit on the 18.7%, about 120 basis points above our model

should we expect to see working capital uptick here in the second half of the year as the company prepares more for that full launch next year?

how does pricing on a Fusion platform stack up to non-fusion assays?

How is your inventory of semis and does that present a headwind or lack, thereof, when you look at the next gantry cycle?

Maybe just an update on where we are in those cycles? And your latest views perhaps heading into one or more of those contracting cycles

What sort of gets you back to 5% to 7%, how long do you think that will take

should we be thinking that sort of the 2014 to 2017 sort of installs from the 3D Tomosynthesis on initial product cycle

frame for us what you would view as the best case outcome in terms of the targeted population in uncontrolled hypertension

with the NTAP and TPT in place now, how much of that population can you go after and how much is still out there that you would need an NCD to sort of address that patient population?

how often does that turn into a new prescriber? How often are these primary care physicians actually new to the CPAP world

Maybe just an update on the impact to the front end of the funnel more specifically

competitive bidding, the proposal is calling for maybe just a consolidation of the number of contract suppliers out there

just an update on the state of the state as it relates to where GLP ones are at the moment

Do you think eventually as commercial payers come in, that you'll have to actually step through CPAP to get to a GLP-1?

Last year, you put in some price increases, both devices and ReSupply